Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Hard Copy Electronic Stakeholder Insight: Inflammatory Bowel Disease - Debate over early aggressive treatment continues Datamonitor, Dec 2007, Pages: 297   Description     Table of Contents     Companies Mentioned        Enquire before Buying    Send to a Friend   Inflammatory bowel disease (IBD) is a chronic inflammatory condition that affects the gastrointestinal tract causing a number of distressing symptoms such as bleeding, diarrhea and abdominal pain. IBD includes key subsets Crohns disease and ulcerative colitis, both of which can significantly impact on the quality of life of an individual. Scope - Analysis of the inflammatory bowel disease market based on a survey of 180 gastroenterologists supported by key opinion leader interviews - Overview of epidemiology and patient segmentation in IBD - Influences on gastroenterologists prescribing behavior and their perception of current brands such as Remicade, Humira, Pentasa, Asacol and Lialda - Assessment of outcomes of treatment with Remicade focusing on treatment failure and reasons for failure Highlights of this title Clinical guidelines recommend a step-up treatment approach. However, Datamonitors survey suggests that currently 20% of patients with severe IBD currently receive an early aggressive treatment approach. There is an ongoing debate among Gastroenterologists and Datamonitor believe this approach will become more commonplace in the future. Remicade remains the first choice biologic therapy in 80% of biologic-naïve patients. However, Humira has distinct advantages over Remicade that will lead to strong. Humira is positioned as a treatment for Remicade-failure patients, but Datamonitors survey suggests currently only 30% of these patients go on to receive Humira. Shires Lialda (mesalazine), recently launched as a once-daily drug, is perceived by gastroenterologists to perform well on patient compliance. In a drug class where there is little differentiation between brands over efficacy and safety, Lialda will provide a clinical advantage thanks to its improved dosing regimen. Key reasons to purchase this title - Target prescribers more effectively, through an understanding of prescribing behavior and influencing factors - Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products - Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies Customers who bought this item also bought Stakeholder Insight: Inflammatory Bowel Disease - Debate over early aggressive treatment continues Early Stage and Discovery Deals: Strategy, Structure and Payment Terms, 2nd Edition The Early Information Society - Information Management in Britain before the Computer Partneringreview 2006: Biopharma Deal Making By Development Stage - Early Stage: Discovery, Lead And Preclinical Building on Early Successes of Immunomodulators in the Fight Against Cancer Early-Stage Pharmaceutical Marketing Budgets: Preparing for Product Launch Cancer Diagnostics: Early Detection of Breast, Prostate and Colorectal Cancer Stakeholder Insight: Insulin Use in Type 2 Diabetes - From Last Resort to Early Intervention

		Top of page

All rights reserved. Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster